Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer
- 208 Downloads
Anaplastic thyroid carcinoma (ATC) is a rare, highly aggressive form of thyroid cancer (TC) characterized by an aggressive behavior and poor prognosis, resulting in patients’ death within a year. Standard treatments, such as chemo and radiotherapy, as well as tyrosine kinase inhibitors, are ineffective for ATC treatment. Cancer immunotherapy is one of the most promising research area in oncology. The PD-1/PD-L1 axis is of particular interest, in light of promising data showing a restoration of host immunity against tumors, with the prospect of long-lasting remissions.
In this study, we evaluated PD-L1 expression in a large series of TCs (20 cases) showing a progressive dedifferentiation of the thyroid tumor from well differentiated TC to ATC, employing two different antibodies [R&D Systems and VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody]. We also tested the anti PD-L1 mAb in an in vivo animal model.
We found that approximately 70–90% of ATC cases were positive for PD-L1 whereas normal thyroid and differentiated TC were negative. Moreover, all analyzed cases presented immunopositive staining in the endothelium of vessels within or in close proximity to the tumor, while normal thyroid vessels were negative. PD-L1 mAb was also effective in inhibiting ATC growth in an in vivo model.
These data suggest that immunotherapy may be a promising treatment specific for ATC suggesting the need to start with clinical TRIALs.
KeywordsPD-L1 PD-1 Anaplastic thyroid cancer Immunotherapy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtain from all individual participants included in the study.
- 2.H. Borghaei, L. Paz-Ares, L. Horn, D.R. Spigel, M. Steins, N.E. Ready, L.Q. Chow, E.E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M.A. Burgio, J. Fayette, H. Lena, E. Poddubskaya, D.E. Gerber, S.N. Gettinger, C.M. Rudin, N. Rizvi, L. Crinò, G.R. Blumenschein Jr, S.J. Antonia, C. Dorange, C.T. Harbison, F. Graf Finckenstein, J.R. Brahmer, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–39 (2015)CrossRefPubMedPubMedCentralGoogle Scholar
- 3.T.K. Choueiri, M.N. Fishman, B. Escudier, D.F. McDermott, C.G. Drake, H. Kluger, W.M. Stadler, J.L. Perez-Gracia, D.G. McNeel, B. Curti, M.R. Harrison, E.R. Plimack, L. Appleman, L. Fong, L. Albiges, L. Cohen, T.C. Young, S.D. Chasalow, P. Ross-Macdonald, S. Srivastava, M. Jure-Kunkel, J.F. Kurland, J.S. Simon, M. Sznol, Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res. 22, 5461–5471 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
- 5.H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, V.A. Lennon, E. Celis, L. Chen, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002). Erratum Nat. Med. 8, 1039 (2002)CrossRefPubMedGoogle Scholar
- 6.J.M. Taube, R.A. Anders, G.D. Young, H. Xu, R. Sharma, T.L. McMiller, S. Chen, A.P. Klein, D.M. Pardoll, S.L. Topalian, L. Chen, Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
- 7.B.R. Haugen, American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer 2017 123, 372–381 (2015)Google Scholar
- 11.D. Viola, L. Valerio, E. Molinaro, L. Agate, V. Bottici, A. Biagini, L. Lorusso, V. Cappagli, L. Pieruzzi, C. Giani, E. Sabini, P. Passannati, L. Puleo, A. Matrone, B. Pontillo-Contillo, V. Battaglia, S. Mazzeo, P. Vitti, R. Elisei, Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr. Relat. Cancer 23, R185–205 (2016)CrossRefPubMedGoogle Scholar
- 15.J.J. Bastman, H.S. Serracino, Y. Zhu, M.R. Koenig, V. Mateescu, S.B. Sams, K.D. Davies, C.D. Raeburn, R.C. McIntyre Jr, B.R. Haugen, J.D. French, Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 101, 2863–73 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
- 19.R. A. DeLellis, R. V. Lloyd, P. U. Heitz, C. Eng, eds. Pathology and Genetics of Tumors of Endocrine Organs. WHO Classification of Tumors, 3rd edn. vol 8, 2004Google Scholar
- 20.P. Workman, E.O. Aboagye, F. Balkwill, A. Balmain, G. Bruder, D.J. Chaplin, J.A. Double, J. Everitt, D.A.H. Farningham, M.J. Glennie, L.R. Kelland, V. Robinson, I.J. Stratford, G.M. Tozer, S. Watson, S.R. Wedge, S.A. Eccles, An ad hoc committee of the National Cancer Research Institute. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555–1577 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
- 21.J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, H.C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T.M. Salay, S. Alaparthy, J.F. Grosso, A.J. Korman, S.M. Parker, S. Agrawal, S.M. Goldberg, D.M. Pardoll, A. Gupta, J.M. Wigginton, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
- 23.F.R. Hirsch, A. McElhinny, D. Stanforth, J. Ranger-Moore, M. Jansson, K. Kulangara, W. Richardson, P. Towne, D. Hanks, B. Vennapusa, A. Mistry, R. Kalamegham, S. Averbuch, J. Novotny, E. Rubin, K. Emancipator, I. McCaffery, J.A. Williams, J. Walker, J. Longshore, M.S. Tsao, K.M. Kerr, PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol. 12, 208–222 (2017)CrossRefPubMedGoogle Scholar
- 24.M.S. Tsao, K.M. Kerr, M. Kockx, M.B. Beasley, A.C. Borczuk, J. Botling, L. Bubendorf, L. Chirieac, G. Chen, T.Y. Chou, J.H. Chung, S. Dacic, S. Lantuejoul, M. Mino-Kenudson, A.L. Moreira, A.G. Nicholson, M. Noguchi, G. Pelosi, C. Poleri, P.A. Russell, J. Sauter, E. Thunnissen, I. Wistuba, H. Yu, M.W. Wynes, M. Pintilie, Y. Yatabe, F.R. Hirsch, PD-L1Immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. J. Thorac. Oncol. 3, 1302–1311 (2018)CrossRefGoogle Scholar
- 27.S. Korehisa, T. Ikeda, S. Okano, H. Saeki, E. Oki, Y. Oda, M. Hashizume, Y. Maehara, A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer. Histopathology 72, 697–703 (2018)CrossRefPubMedGoogle Scholar